Abstract B05: Basic research and translational medicine of bladder cancer in China
Authors: Cai Zhiming 
Published: August 2020

Abstract
Over the past decade, the basic medical research has developed rapidly in China, and more attention is focused on the clinical application of scientific discoveries, resulting in increased contribution to human science and technology. Like other major diseases, the basic research and translational medicine of bladder cancer has been significantly improved, and the clinical translational research also showed a promising tendency. Zhiming Cai's team launched the “Genitourinary Tumor Genome Project” and established a biologic sample bank and biologic repositories for genitourinary tumors in 2010. The Digital Hospital for Bladder Cancer is also under construction. Based on the CRISPR-Cas9, our team synthesized the logical “AND” gate genetic circuits of bladder cancer cells. With discovered targets, the engineered cells were developed and applied to CAR-T and TCR-T clinical trials of bladder cancer. About 70 patients from the world were treated and satisfying clinical results were achieved. One patient with recurrent bladder cancer had stopped recurring for more than 3 years after TCR-T treatment. Song Wu's team has made great progress in bladder cancer stem cell research and the urine test for early detection of bladder cancer. Jian Huang's team launched the “Chinese Bladder Cancer Consortium” in 2013 and organized an annual national academic conference where hundreds of participants came together to expand the research of bladder cancer in China. Tianxin Lin's team identified a predictive marker for VEGF-C antibody therapy, providing a systematic solution for lymphatic metastasis of bladder cancer. Fangjian Zhou's team confirmed the high expression of exosomal circPRMT5 is a new biomarker for predicting lymphatic metastasis. Zusen Fan's team focused on the regulation of stem cell origin of bladder cancer, urine cell cytology diagnosis, and immunotherapy based on antibody BCMab1. Pingchou Han and Baiye Jin's team developed a novel microfluidic approach for detection of bladder cancer cells. Tingyi Wen and Chong Li's team identified a novel signal, the KMT1A-GATA3-STAT3 circuit, which promoted the self-renewal and tumorigenicity of human bladder cancer stem cells. Dingwei Ye and Jiejie Xu's team reveal the immunologic characteristics of tumors in the Chinese bladder cancer population. Also, Ye's team found a rare polymorphism in the UHRF1BP1 gene that was related to the bladder cancer incidence in Chinese. Jun Yan's team revealed overexpression of Wnt7a activated the Wnt/β-catenin signaling, which may induce the metastasis of bladder cancer. Zhengdong Zhang's team identified a new locus site of intron CWC27, which was associated with bladder cancer risk. Zhiping Wang's team found that the variants of SNPs in multiple DNA repair genes as well as some haplotypes were highly related with the bladder cancer, of which two locus sites of XRCC3 gene showed significant relation with the bladder cancer occurring in the Han population of Northwest China.
Note: This abstract was not presented at the conference.
Citation Format: Zhiming Cai. Basic research and translational medicine of bladder cancer in China [abstract]. In: Proceedings of the AACR Special Conference on Bladder Cancer: Transforming the Field; 2019 May 18-21; Denver, CO. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(15_Suppl):Abstract nr B05.